When used for maintenance, adding an immunomodulator treatment to Humira therapy should be considered to decrease the risk of ...

As of today, July 1st, Cyltezo (adalimumab-adbm) is commercially available in the U.S. It is the first and thus far only therapeutically interchangeable Humira-referenced biosimilar approved by ...

My most important ABBV-specific short-term danger is ongoing sales erosion of Humira due to biosimilars. Although my fundamental analysis demonstrated the company is making tremendous progress ...

As AbbVie transitions away from Humira, it faces the challenge of establishing and maintaining leadership positions for Skyrizi and Rinvoq in a highly competitive landscape. There is a risk that ...

Offsetting Humira's expected declines ... The lower single-product concentration risk combined with strong traction with the current product portfolio helps support a wide moat for the firm.

Humira is starting to feel the effects of lower ... Last month, the FDA added a boxed warning to Xeljanz’ label for increased risk of potentially fatal blood clots, while Olumiant has been ...

Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...

The impact of this decline could be substantial, given that Humira has been a major revenue driver for AbbVie. There is a risk that the rate of erosion could be faster than anticipated ...